United States v. Abbott Laboratories

District Court, S.D. California·Decided May 14, 2024·No. 3:20-cv-00286·Unknown

Opinion

UNITED STATES OF AMERICA, et Case No.: 3:20-cv-286-W-MSB al.; ex rel. EVEREST PRINCIPALS, LLC, ORDER OVERRULING OBJECTION TO MAGISTRATE Plaintiffs and Relator, JUDGE’S ORDER DENYING v. MOTION TO COMPEL [DOC. 123] ABBOTT LABORATORIES, et al., Defendants.

Pending before the Court is the objection ([Doc. 123], “Objection”) of Defendants Abbott Laboratories, Abbot Laboratories Inc., Abbott Cardiovascular Systems Inc., and Abbott Vascular Inc. (collectively, “Defendants” or “Abbott”) to U.S. Magistrate Judge Michael S. Berg’s order ([Doc. 121], “Discovery Order”) denying Abbott’s Motion to Compel ([Doc. 114], “MTC”) the production of Plaintiff-Relator Everest Principals, LLC’s (“Relator”) disclosure statement and subsequent submissions/communications with the government. Relator opposes the Objection. ([Doc. 124], “Opposition”.) The Court decides the matter on the papers submitted and without oral argument. See Civ. R. 7.1(d)(1). For the following reasons, the Court OVERRULES the Objection and AFFIRMS the Magistrate Judge’s Discovery Order.

This is a qui tam case brought by Relator against Abbott on behalf of the United States and several states for allegedly violating the federal False Claims Act and several state law equivalents (collectively, the “False Claims Act”). (See [Doc. 85], “Third Amended Complaint” or “TAC” at ¶¶ 6-10.) Specifically, the Complaint alleges that “Defendants engaged in an unlawful, systematic and nationwide scheme of providing illegal kickbacks to physicians and hospitals . . . .” in an effort to increase sales of Abbott’s MitraClip medical device. (TAC at ¶ 2.) According to Relator, this “scheme” “knowingly caused the submission of thousands of false claims for payment to Government Healthcare Programs.” (Id. at ¶ 3.) In an effort to encourage insiders to disclose fraud against the government, the False Claims Act allows private individuals to bring civil actions on the government’s behalf (and retain portion of the award) via qui tam actions. Ebeid ex rel. United States v. Lungwitz, 616 F.3d 993, 995 (9th Cir. 2010). When filing such a complaint, a relator must provide the government with “[a] copy of the complaint and written disclosure of substantially all material evidence and information the person possesses.” 31 U.S.C. § 3730(b)(2). That way, the government can make a “well-reasoned decision on whether it should participate in the filed lawsuit or allow the relator to proceed alone” E.g., United States ex rel. Bagley v. TRW, Inc., 212 F.R.D. 554, 555 (C.D. Cal. 2003) (citations omitted). Here, Relator filed its original complaint under seal on February 14, 2020. ([Doc. 1].) As required by the False Claims Act, Relator provided the Department of Justice with a copy of the complaint and “written disclosure of substantially all material evidence and information the person possesses” (“Disclosure Statement”). ([Doc. 113], at 3; [Doc. 114-1] at 5.) Apparently, there was an unspecified number of attachments to the Disclosure Statement and Relator had some subsequent communications with government entities regarding this case (the “Subsequent Communications”). (Id.) After the relevant government entities declined to intervene in the case, the Court unsealed the Complaint on March 25, 2021. ([Docs. 8, 9.]) On July 12, 2023, Abbott served Relator with their Requests for Production – Set One (“RFP”). ([Doc. 114-2] at 2.) At issue here, RFP No. 4 sought “[a]ll written disclosure communications between [Relator] and any government agency relating to Abbott or this litigation.” (Id. at 2-3.) Similarly, RFP No. 5 sought “[a]ll communications (excluding privileged communications solely between you and your counsel of record in this action) relating to any allegation that Abbott violated any law or to the claims or allegations of the Third Amended Complaint and Exhibits A and B thereto.” (Id. at 3.) Relator timely objected to the RFPs 4 and 5, on the grounds that, among other things, they sought information constituting attorney work product. Relator then refused to produce the requested documents. ([Doc. 114-4] at 3-4.) Ultimately, Abbott filed its MTC, asking the Magistrate Judge to order Relator to (1) produce its Disclosure Statement; (2) produce the Subsequent Communications; and (3) identify which already produced documents were attached to the Disclosure Statement. ([Doc. 114-1] at 7-14.) To overcome Relator’s work product assertions, Abbott argued that the materials sought would help “illuminate[] the factual bases” for Relator’s claims and “could reveal inconsistencies between Relator’s representations to the government and its litigation positions”—which could go towards proving Abbott’s asserted “public disclosure” defense. (See id. at 6-9.) From there, Abbott urged the Magistrate Judge to conduct an in camera review of the materials in order to redact any “opinion” work product before producing to Abbott. (Id.) The Magistrate Judge denied the MTC, reasoning that Abbott’s “vague” and “generic” assertions of the Public Disclosure Defense did not demonstrate a “substantial need” for the materials. (See Discovery Order at 11-12.) Subsequently, Abbott filed the Objection to the Magistrate Judge’s Discovery Order currently before the Court. (Objection.) However, Relator has produced all documents that it relied on to generate the Disclosure Statement. ([Doc. 113] at 6.) Under Rule 72(a), a party may file an objection to a magistrate judge’s order within 14 days of being served a copy of the order. FED. R. CIV. P 72(a). From there, the district judge “must consider timely objections and modify or set aside any part of the order that is clearly erroneous or is contrary to law.” Id. (emphasis added). Under this standard, the district court must defer to factual findings or discretionary decisions of the magistrate judge, disturbing those findings/decisions only when “the district court is left with the definite and firm conviction that a mistake has been committed.” Kurin, Inc. v. Magnolia Med. Techs., Inc., 2019 WL 5422931, at *2 (S.D. Cal. Oct. 23, 2019) (citing Grimes v. City and Cty. of San Francisco, 951 F.2d 236, 240 (9th Cir. 1991); Concrete Pipe & Prods. v. Constr. Laborers Pension Trust, 508 U.S. 602, 623 (1993); and Security Farms v. Int'l Brotherhood of Teamsters, 124 F.3d 999, 1014 (9th Cir. 1997)). District courts review a magistrate judge’s legal conclusions de novo. Id. Abbott asks the Court to compel three things from Relator: (A) to produce the Disclosure Statement; (B) to produce the Subsequent Communications; and (C) to identify which documents that have already been produced were attached to the Disclosure Statement. (Objection at 12-29.) A. The Disclosure Statement Relator was statutorily required by the FCA to provide the government with Disclosure Statement laying out out “all material evidence and information the [Relator] possesses.” 31 U.S.C. § 3730(b)(2). With this in mind, it is unsurprising that “the majority of courts have found that the written disclosure statement provided in compliance with the FCA falls under the work-product doctrine as a document prepared in anticipation of litigation . . . .” Bingham v. Baycare Health Sys., 2016 WL 1546504, at *4 (M.D. Fla. Apr. 15, 2016) (emphasis added) (citing U.S. ex rel. Spletzer v. Allied Wire & Cable, Inc., 2015 WL 7014620 (E.D. Pa. Nov. 12, 2015); U.S. ex rel. Fisher v. Homeward Residential, Inc., 2015 WL 4610284 (E.D. Tex. July 31, 2

Free access — add to your briefcase to read the full text and ask questions with AI

United States v. Abbott Laboratories, (S.D. Cal. 2024).

United States v. Abbott Laboratories (United States v. Abbott Laboratories) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related